|
Workshop
[Free Online Workshop] Career Transition for Research Scientists: Business Development & BioPartnering
Speakers:
Lesley Stolz (J&J), Jimmy Zhang (previously Merck, J&J, Lilly), Cheni Kwok (Linear Dreams), Sarah Bodary (Darwin Bodary Consulting), Lizabeth Leveille (Merck), Jennifer Leeds (Retired from Novartis)
Organizers:
Toby Freedman (Synapsis Search Biotech Recruiting), Rachel Kindt (Rachel Kindt Consulting), Sandra Morris (MorTil Consulting), Dean Wilson (PBSS)
Date:
2024-11-13
Time:
8:30-12:30 Pacific Time
Registration fee:
Free
Location:
Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2024-11-12
(it will close sooner if the seating cap is reached)
About the Topic
| Time (PT) |
Topic |
Speaker |
| 8:30-8:40 am |
PBSS Welcome |
Dean Wilson, PhD, PBSS |
| 8:40-9:15 am |
Business Development Overview |
Lesley Stolz, PhD, VP, Early Innovation Partnering, Johnson & Johnson Innovation |
| 9:15-9:40 am |
Panelist Presentation |
Jimmy Zhang, PhD, MBA, Biotech BD Executive, previously at Merck, J&J, Lilly Asia Ventures |
| 9:40-10:05 am |
Panelist Presentation |
Cheni Kwok Ph.D. CLP, Managing Partner & Founder, Linear Dreams LLC |
| 10:05-10:30 am |
Panelist Presentation |
Sarah Bodary, PhD, Biotech Advisor/Investor, Darwin Bodary Consulting |
| 10:30-10:45 am |
Break |
|
| 10:45-11:10 am |
Panelist Presentation |
Lizabeth Leveille, MS, MBA, VP, BD&L; Head, Boston & European Innovation Hubs & Discovery Transactions, Merck & Co. Inc. |
| 11:10-11:35 pm |
Panelist Presentation |
Lesley Stolz, PhD, VP, Early Innovation Partnering, Johnson & Johnson Innovation |
| 11:35-12:00 pm |
Panelist Presentation |
Jennifer Leeds, PhD, Retired from Novartis BD as Head of Search and Evaluation, West Coast and Canada |
| 12:00-12:30 pm |
Panel Discussion |
All Speakers (Moderators : Dean and Rachel) |
2024-09-10, [In-Person] Translational PK/PD and Human Dose Projection for Antibodies/ADCs and Novel Therapeutic Modalities
|
2024-09-20, [In-Person] Nonclinical Safety Assessments of Biologics and Other Novel Modalities for IND/NDA/BLA Filings
|
2024-09-25, [Free Online] Development of Protein Degraders: Computational Modeling, Medicinal Chemistry and Early Development
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
2024-10-25, [Free Online Workshop] Unleashing the Power of Real-World Evidence / Data (RWE/RWD) to Facilitate Drug Discovery, Development, and Beyond
|
2024-11-01, [In-Person] Clinical Pharmacology Studies on Hepatic and Renal Impairments for NDA Filing: Strategies, Design, Conduct, Analysis and Regulatory Aspects
|
2024-11-15, [In-Person] Current State of Bioanalysis for Biologics and Cell/Gene Therapy Products: Refining Established Approaches for New Complex Therapies
|
2024-12-13, Why All These New Modalities?
|
2025-01-22, [In-Person] Small-Molecule Formulation for Discovery & Early Development (jointly by PBSS / AAPS-BADG / Syner-G)
|
2025-02-06, [In-Person] Intellectual Property (IP) Strategies and Best Practices
|
|
Ads (in random order)
Submit a Text Ad
($250 for 2 months)
Simulations Plus
GastroPlus X: Science, models & refined algorithms—now with intuitive interface, faster processing & streamlined workflows for faster PBPK modeling.
|
PharmaResources
Top-tier small molecule CRO/CDMO offering comprehensive supports from Medicinal Chemistry, DMPK, and CMC to GMP manufacturing for commercialization.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Allucent
Bringing innovation to Biotech w/ClinPharm Modeling & Simulation services to inform dose, design, modeling + development strategies.
|
Submit a Text Ad
|